Despite Headwinds, Biosimilars Market Is Growing in 2024
The Food and Drug Administration (FDA) has approved a record number of biosimilars in 2024, and the year is only half over.
Patent Thicket Déjà Vu
Tuesday’s Senate Judiciary Committee hearing on drug competition was largely as expected: Committee members voiced support for legislative reforms to address features of the current patent system that result in abuses that excessively limit competition.
Will Congress Finally Act on Patent Thickets?
In 2019, the Committee moved legislation to prevent brand drug companies from amassing superfluous patents around their products—a strategy that, as we’ve written before, is uniquely problematic in the United States.
Current and Future State of US Biosimilars
Fourteen years ago, Congress established a regulatory pathway for biosimilars, direct competitors to branded biologic drugs.
Trends in the US Insulin Market: New Prices, New Players, New Dynamics
Insulin, a drug first developed more than 100 years ago, has experienced a surge in political interest in recent years following dramatic price hikes.
Biden Budget Proposes a Step Toward Biologic Drug Competition
Politicians—Democrats and Republicans alike—regularly complain about high drug prices and the need for policy changes to make prescription medicines more affordable for patients (read: voters).
- Despite Headwinds, Biosimilars Market Is Growing in 2024
- IRS says it will deny most claims of pandemic tax credit for employers
- Trump Talks Taxes and Tariffs
- Beware the Baseline Manipulator
- Patent Thicket Déjà Vu
- Will Congress Finally Act on Patent Thickets?
- Federal Debt: The Baseline and Options for Reform
- Navigating the Upcoming Tax Cliff: Can Republicans Prevent a Tax Increase Without Adding to the Deficit?
- Current and Future State of US Biosimilars
- Trends in the US Insulin Market: New Prices, New Players, New Dynamics
